To determine how ageing affects the mode and efficiency of β-cell reconstitution after β-cell loss, we administered diphtheria toxin (DT) to adult (2-month-old) or aged (1-and 1.5-year-old) *RIP-DTR* mice, whose β-cells bear DT receptors ^[@R3]^, and followed them for up to 14 months. Collectively, we found that α-to-β cell conversion is the main mechanism of insulin cell generation after massive β-cell loss in adult post-pubertal mice, whether middle-aged or very old, and α-cells are progressively recruited into insulin production with time ([Extended Data Fig.1](#F4){ref-type="fig"}; [Supp. Tables S1](#SD1){ref-type="supplementary-material"}-[5](#SD1){ref-type="supplementary-material"}).

In this study we focused on the regeneration potential during early postnatal life by inducing β-cell ablation before weaning, at 2 weeks of age ([Fig. 1a](#F1){ref-type="fig"}). We found that prepubescent mice rapidly recover from diabetes after near-total β-cell loss: four months later all younglings were almost normoglycemic, thus displaying a faster recovery relative to adults ([Fig. 1b](#F1){ref-type="fig"} and [Extended Data Fig.2a,b](#F5){ref-type="fig"}; see [Extended Data Fig.1a](#F4){ref-type="fig"}).

Histologically, 99% of the β-cells were lost at 2 weeks following DT administration ([Fig. 1c](#F1){ref-type="fig"}). The β-cell number increased by 45-fold 4 months after ablation, representing 23% of the normal age-matched β-cell mass ([Fig. 1c](#F1){ref-type="fig"}; [Supp. Table S6](#SD1){ref-type="supplementary-material"}) and correlating with normoglycemia recovery ^[@R1]^.

All animals remained normoglycemic during the rest of their life ([Supp. Table S6](#SD1){ref-type="supplementary-material"}). Mice were neither intolerant to glucose nor insulin resistant during the period of analysis, up to 15 months after injury ([Extended Data Fig. 2c-e](#F5){ref-type="fig"}).

We investigated whether the new insulin^+^ cells were reprogrammed α-cells, as in adults, using *Glucagon-rtTA*; *TetO-Cre*; *R26-YFP; RIP-DTR* pups ([Fig. 1d](#F1){ref-type="fig"}). We observed that almost no insulin^+^ cell co-expressed YFP or glucagon ([Supp. Table S7](#SD1){ref-type="supplementary-material"}), indicating that α-cells do not reprogram in younglings.

We further explored the age-dependency of rescue after near-total β-cell loss. To this aim, normoglycemic 5-month-old mice, which had recovered from β-cell loss at 2 weeks of age, were re-administered DT to ablate the regenerated insulin^+^ cells. One month following the second ablation, 30% of the insulin-containing cells also contained glucagon ([Extended Data Fig.2f](#F5){ref-type="fig"}; [Supp. Table S8](#SD1){ref-type="supplementary-material"}), like β-cell-ablated adults ([Extended Data Fig. 1k](#F4){ref-type="fig"}), confirming that the pre-pubertal regeneration mechanism is restricted temporally.

We measured proliferation rates at different time-points during 2 months of regeneration. The proportion of Ki67-labeled insulin^+^ cells was very low ([Extended Data Fig.2g](#F5){ref-type="fig"}; [Supp. Table S9](#SD1){ref-type="supplementary-material"}), indicating that neither escaping β-cells nor regenerated insulin^+^ cells proliferate during this period. However, there was a transient 3.5-fold increase in the number of insular Ki67^+^ cells 2 weeks after ablation, unlike in adult animals ([Extended Data Fig.2h](#F5){ref-type="fig"}; [Supp. Table S10](#SD1){ref-type="supplementary-material"}). Replicating cells were hormone-negative, chromogranin A-negative, and were not lineage-traced to either α- or escaping β-cells ([Extended Data Fig.2i,j](#F5){ref-type="fig"}).

Coincident with the peak of islet cell proliferation we noticed in pups a 4.5-fold decrease in the number of somatostatin-producing δ-cells (from 13 to 3 δ-cells/islet section; [Extended Data Fig.3a](#F6){ref-type="fig"}; [Supp. Table S11](#SD1){ref-type="supplementary-material"}) and a 76-fold decrease of *somatostatin* transcripts ([Extended Data Fig.3b](#F6){ref-type="fig"}), without indication of increased islet cell death. We therefore lineage-traced δ-cells and observed that regenerated insulin-producing cells were dedifferentiated δ-cells. At 2 months of age in *Somatostatin-Cre; R26-YFP; RIP-DTR* mice, about 81% of δ-cells were YFP^+^ in the absence of β-cell ablation, whereas α- and β-cells were labeled at background levels (0.9% for β-cells and 0.2% for α-cells; [Extended Data Fig.3c,d](#F6){ref-type="fig"}, [Supp. Table S12](#SD1){ref-type="supplementary-material"}). During β-cell reconstitution in pups, 2 weeks after β-cell ablation, 80% of YFP^+^ cells were proliferating (Ki67^+^) and somatostatin-negative ([Fig. 2a,b](#F2){ref-type="fig"}; [Supp. Table S13](#SD1){ref-type="supplementary-material"}), while most Ki67^+^ cells were YFP-labeled (85%; [Supp. Table S14](#SD1){ref-type="supplementary-material"}).

These observations suggest that in β-cell-ablated pre-pubertal mice most δ-cells undergo a loss of somatostatin expression and enter the cell cycle.

We further investigated the fate of proliferating dedifferentiated δ-cells. At 1.5 months post-ablation, most insulin^+^ cells expressed YFP (90%), indicating their δ-cell origin ([Fig. 2c,d](#F2){ref-type="fig"}; [Supp. Table S15](#SD1){ref-type="supplementary-material"}). Furthermore, in contrast to non-ablated age-matched controls, where all YFP^+^ cells were somatostatin^+^ (\>99%), about half of YFP^+^ cells were insulin^+^ after 1.5 months of regeneration (45%; [Fig. 2e](#F2){ref-type="fig"}; [Supp. Table S16](#SD1){ref-type="supplementary-material"}). This reveals that half of the progeny of dedifferentiated δ-cells becomes insulin expressers. Bihormonal somatostatin^+^/insulin^+^ cells were rare ([Supp. Table S17](#SD1){ref-type="supplementary-material"}).

Combined, these observations show that at the cell population level, each dedifferentiated δ-cell yields one insulin expresser cell and one somatostatin^+^ cell([Extended Data Fig.4](#F7){ref-type="fig"}).

We confirmed with two other assays that regeneration and diabetes recovery in juvenile mice are δ-cell-dependent: by inducing β-cell destruction with streptozotocin (STZ) instead of DT ([Extended Data Fig.5a-c](#F8){ref-type="fig"}), and by co-ablating β- and δ-cells simultaneously in *Somatostatin-Cre; R26-YFP; R26-iDTR; RIP-DTR* pups. In absence of δ-cells there was no insulin^+^ cell regeneration, and no recovery ([Fig. 2f](#F2){ref-type="fig"}).

In adults, δ-cells neither de-differentiated nor proliferated following β-cell ablation ([Extended Data. Fig.5d,e](#F8){ref-type="fig"}; [Supp. Table S20](#SD1){ref-type="supplementary-material"}). Nevertheless, like α-cells, a few δ-cells reprogrammed into insulin production, so that after 1.5 month of regeneration 17% of the rare insulin-producing cells were YFP^+^, i.e. δ-cell-derived ([Extended Data Fig. 5f-h](#F8){ref-type="fig"}; [Supp. Tables S21](#SD1){ref-type="supplementary-material"}, [S22](#SD1){ref-type="supplementary-material"}).

By transplanting *Somatostatin-Cre; R26-YFP; RIP-DTR* juvenile islets into adult wild-type mice we observed that, following β-cell ablation, the newly formed insulin^+^ cells were reprogrammed δ-cells, thus showing that the pup-specific regeneration is intrinsic to islets ([Extended Data Fig.6](#F9){ref-type="fig"}).

Contrary to β-cells in age-matched adult mice, δ-cell-derived insulin^+^ cells replicated transiently ([Extended Data Fig.7a](#F10){ref-type="fig"}; [Supp. Table S23](#SD1){ref-type="supplementary-material"}); the β-cell mass thus reached between 30% to 69% of the normal values, and remained stable for life (above, [Supp. Table S6](#SD1){ref-type="supplementary-material"}).

We characterized the δ-cell-derived insulin^+^ cells at the gene expression level by qPCR. We first compared islets isolated 2 weeks after β-cell ablation or after recovery (4 months post-DT), with age-matched control islets. Expression of all the β-cell-specific markers tested was robustly increased in recovered mice ([Extended Data Fig.7b](#F10){ref-type="fig"}). We also compared regenerated insulin^+^ cells with native β-cells using sorted mCherry^+^ cells obtained from either recovered or unablated age-matched (4.5-month-old) *insulin-mCherry; RIP-DTR* mice ([Extended Data Fig.7c](#F10){ref-type="fig"}). The two cell populations were very similar ([Extended Data Fig.7d](#F10){ref-type="fig"}), yet the δ-cell-derived replicating β-cells displayed apotent downregulation of cyclin-dependent kinase inhibitors and regulators ([Extended Data Fig.7e,f](#F10){ref-type="fig"}). This suggests that reconstituted insulin^+^ cells are like β-cells with transient proliferation capacity. Future studies will establish whether reconstituted (δ)β-like cells are true equivalents to native β-cells.

qPCR and lineage-tracing analyses on islets isolated from pups at different regeneration time-points, together with *Ngn*3 KO induction after β-cell ablation, revealed that Ngn3transcription is required for the δ-to-insulin^+^ cell conversion to occur ([Extended Data Fig.8a-k](#F10){ref-type="fig"}, [Supp. Tables S24](#SD1){ref-type="supplementary-material"}-[S29](#SD1){ref-type="supplementary-material"}). Of note, brief expression of *Ngn3* is a feature of islet precursor cells in the embryonic pancreas ^[@R4]^. Together, these observations are compatible with a model in which β-cell reconstitution after ablation in younglings occurs following a sequence of events: δ-cells dedifferentiate, replicate once and then half of the progeny activates *Ngn3* expression before insulin production ([Fig. 2g](#F2){ref-type="fig"}). This was tested in a *combined* double lineage-tracing experiment using *Somatostatin-Cre; R26-Tomato; Ngn3-YFP; RIP-DTR* mice. Six weeks post-β-cell ablation, insulin^+^ cells in younglings were Tomato^+^/YFP^+^ ([Extended Data Fig.8k](#F10){ref-type="fig"}).

One key reprogramming and cell cycle entry player is FoxO1, a transcription factor whose downregulation triggers *Ngn3* expression in human fetal pancreatic explants ^[@R5]^ and favors insulin production in Ngn3^+^ entero-endocrine progenitors ^[@R6]^. FoxO1, usually in cooperation with TGFβ/SMAD signaling ^[@R7],[@R8]^, inhibits cell proliferation through the transcriptional regulation of cell cycle inhibitors and activators ^[@R18]^, and is involved in cellular senescence ^[@R7]^ ([Extended Data Fig.9a](#F12){ref-type="fig"}). We then explored the FoxO1 molecular network in purified adult or juvenile δ-cells before and after (1-week) β-cell ablation, using *Somatostatin-Cre; R26-YFP; RIP-DTR* mice.

δ-cells displayed a divergent regulation of *FoxO1* in injured juvenile and adult mice. Consistent with *FoxO1* downregulation in juvenile δ-cells, *PDK1* and *AKT* levels were increased, *cdkn1a/p21* and *cdkn2b/p15Ink4b* were downregulated, and *CKS1b*, *CDK2* and *SKP* were upregulated ([Fig. 3a](#F3){ref-type="fig"}), which is compatible with the proliferative capacity of juvenile δ-cells after β-cell ablation. The opposite was found in δ-cells of ablated adults ([Fig. 3a](#F3){ref-type="fig"}; [Extended Data Fig.9b](#F12){ref-type="fig"}).

Moreover, in δ-cells of younglings, but not in adults, there was a robust upregulation of BMP1/4 downstream effectors ([Fig. 3b](#F3){ref-type="fig"}) ^[@R9],[@R10]^. Inversely, TGFβ pathway genes were upregulated in δ-cells of regenerating adults ([Fig. 3b](#F3){ref-type="fig"}), which is compatible with the senescence scenario ^[@R7]^ involving PI3K/FoxO1 and TGFβ/SMAD cooperation to maintain differentiation and cycle arrest ([Extended Data Fig9a,b](#F12){ref-type="fig"}).

In summary, PI3K/AKT and SKP2/SCF pathways potentially cooperate to downregulate *FoxO1* in δ-cells of regenerating younglings. Also, upregulation of BMP effectors (*ID1* and *ID2*) could contribute to δ-cell dedifferentiation and proliferation, as observed in other systems ^[@R9],[@R10]^ ([Fig. 3c](#F3){ref-type="fig"}). Conversely, the PI3K/AKT pathway remained downregulated in δ-cells of ablated adults, which would allow FoxO1 to impede proliferation and dedifferentiation, probably through partnership with previously described SMADs ^[@R11]^ ([Extended Data Fig.9b](#F12){ref-type="fig"}).

We then checked whether a transient FoxO1 inhibition in adult mice would lead to a juvenile-like δ-to-β cell conversion. Indeed, inactivation of FoxO1 in β-cells causes their dedifferentiation ^[@R12]^. Here, *Somatostatin-Cre; R26-YFP; RIP-DTR* β-cell-ablated adult mice were given a FoxO1 inhibitor (AS1842856) for 1 week, either immediately following ablation ([Fig. 3d](#F3){ref-type="fig"}) or 1 month later ([Extended Data Fig.10f](#F13){ref-type="fig"}; [Supp. Tables S37](#SD1){ref-type="supplementary-material"}-[S39](#SD1){ref-type="supplementary-material"}) ^[@R13],[@R14]^. While FoxO1 inhibition in non-ablated controls had minimal effect on insulin expression ([Extended Data Fig.10a-d](#F13){ref-type="fig"}; [Supp. Tables S30](#SD1){ref-type="supplementary-material"}-[S32](#SD1){ref-type="supplementary-material"}), regeneration in diabetic mice was improved: insulin^+^ cells were more abundant (11-fold; [Fig. 3e,f](#F3){ref-type="fig"}; [Supp. Table S33](#SD1){ref-type="supplementary-material"}), and were reprogrammed δ-cells (93% were YFP^+^, [Fig. 3g](#F3){ref-type="fig"}; [Supp. Table S34](#SD1){ref-type="supplementary-material"}). One-fourth of the YFP^+^ cells expressed insulin only ([Fig. 3h](#F3){ref-type="fig"}; [Extended Data Fig.10e](#F13){ref-type="fig"}; [Supp. Tables S35](#SD1){ref-type="supplementary-material"}, [S36](#SD1){ref-type="supplementary-material"}), revealing that, like in younglings, an important fraction of δ-cells had converted to insulin production.

These results support the involvement of a regenerative FoxO1 network and confirm that δ-cell conversion can be pharmacologically induced in diabetic adults. FoxO1 blockade has a pleiotropic effect: inhibition of hepatic gluconeogenesis ^[@R13],[@R14]^ and promotion of δ-cell reprogramming (this study).

A century ago Morgan coined the terms *epimorphosis* and *morphallaxis* to designate, respectively, regeneration involving either cell dedifferentiation and proliferation or direct conversion from one cell type into another without proliferation ^[@R15]^. Here we report in mammals an age-dependent switch ("adult transition") between epimorphic regeneration during youth, and a less efficient yet persistent throughout life proliferation-independent morphallactic mechanism.

Our findings uncover a novel role for δ-cells; perhaps somatostatin^+^ cells in the stomach, intestine or hypothalamus share the same capabilities. Intra-islet cell plasticity triggered by the disappearance of β-cells is influenced by age: the proliferation decline in ageing cells ^[@R16]^ would explain the need of an "adult transition". Although less efficient, α-cell plasticity remains long-time after β-cell loss since it is proliferation-independent.

These phenomena might be translatable to humans, for there is efficient β-cell regeneration in children with T1D or after pancreatectomy ^[@R3],[@R17]-[@R19]^, and glucagon/insulin bihormonal human cells have been described upon epigenetic manipulation *ex vivo* ^[@R20]^, and in diabetic patients ^[@R21],[@R22]^. Knowing also that only a small fraction of the α-cell population is sufficient to maintain glucagon signaling ^[@R23]^, understanding the nature of the diverse forms of intra-islet cell conversion might provide new opportunities to fostering the formation of (α)β-like and (δ)β-like cells.
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![Maintenance of α-cell plasticity in diabetic aged mice\
**a)** Evolution of glycemia in β-cell-ablated adults (middle-aged) and aged mice. The "area under the curve" (AuC) in middle-aged (2-month-old, n=4) and aged (1- and 1.5-year-old, n=5 and n=3) mice before and after stopping insulin administration revealed no statistical difference between groups (Welch's test \[p~\[0-45mpa\]~=0.1029, 0.3321; p~\[4.5-7mpa\]~=0.1748, 0.5007\], one-way Anova \[p=0.1161; p=0.2681\], and Mann Whitney \[p=0.1640, 0.4519\]). **b)** Evolution of glycemia in 14 aged mice during 14 months post-ablation ("mpa"). Mice were treated with insulin for 4.5 months; most of them (5/7 in each group) subsequently recovered from diabetes. **c-e)** Pancreatic islets before **(c)** and after **(d, e)** β-cell ablation in 1.5-year-old mice; β-cell mass increases 3.5-fold between 0.5 and 1 mpa, 12-fold at 7 mpa and 32-fold at 14 mpa, in all age groups. 0.3% and 4.4% indicate β-cell mass relative to unablated controls ([Supp. Table S1](#SD1){ref-type="supplementary-material"}, *2-month-old:* n~(0.5mpa)~=4, n~(1mpa~)=4, n~(7mpa)~=4; *1-year-old:* n~(0.5mpa)~=5, n~(1mpa)~=5, n~(7mpa)~=5, n~(14mpa)~=8; *1.5-year-old:* n~(0.5mpa)~=3~,~ n~(1mpa)~=3, n~(7mpa)~=3 , n~(14mpa)~=8). **f)** β-cell proliferation is very low in aged mice, whether control (1.5%, n=8, 39,790 insulin^+^-cells scored) or ablated (0.2%, n=6, 938 790 insulin^+^-cells scored) ([Supp. Table S2](#SD1){ref-type="supplementary-material"}). **g)** Proportion of insulin^+^ cells also containing glucagon after DT is not different between groups ([Supp. Table S3](#SD1){ref-type="supplementary-material"}; *control:* n~\[2-month-old\]~=3, n~\[1-year-old\]~=3, n~\[1.5-year-old\]~=3; *0.5mpa:* n~\[2-month-old\]~=5, n~\[1-year-old\]~=5, n~\[1.5-year-old\]~=6; *1mpa:* n~\[2-month-old\]~=4, n~\[1-year-old\]~=6, n~\[1.5-year-old\]~=4; *7mpa:* n~\[2-month-old\]~=5, n~\[1-year-old\]~=5, n~\[1.5-year-old\]~=6; one-way Anova \[p=0.6796, 0.4297, 0.9266, 0.2411\]); note that 40% of the cells containing insulin at 1 mpa also contained glucagon. The proportion of glucagon^+^/insulin^+^ cells remains constant between 0.5 and 7 mpa, while the number of insulin^+^ cells increases with time **(e,** [Supp. Table S1](#SD1){ref-type="supplementary-material"}), suggesting that there is acumulative recruitment of α-cells into insulin production. **h)** Islet with YFP^+^/glucagon^+^/insulin^+^ cells in 1-year-old *Glucagon-rtTA; TetO-Cre; R26-YFP; RIP-DTR* mice, 7 mpa; rtTA expression allows the selective irreversible YFP-labeling of adult α-cells upon administration of doxycycline (DOX) before β-cell ablation. **i)** Proportion of YFP-labeled insulin-expressing cells in DOX-treated mice. 80% of insulin^+^ cells are YFP^+^ after 7 mpa, in all age groups ([Supp. Table S4](#SD1){ref-type="supplementary-material"}; *control*: n~\[2-month-old\]~=3, n~\[1-year-old\]~=3, n~\[1.5-year-old\]~=3; *1mpa*: n~\[2-month-old\]~=5, n~\[1-year-old\]~=3, n~\[1.5-year-old\]~=3; *7mpa*: n~\[2-month-old\]~=5, n~\[1-year-old\]~=5, n~\[1.5-year-old\]~=5; one-way Anova \[p=0.9417, 0.8910, 0.9641\]). **j,k)** YFP^+^/glucagon^+^/insulin^+^ cells at 7 mpa, following a DOX pulse-labeling at 5.5 months after β-cell loss ([Supp. Table S5](#SD1){ref-type="supplementary-material"}, control: n~\[1-year-old\]~=5, n~\[1.5-year-old\]~=5; 7mpa: n~\[1-year-old\]~=5, n~\[1.5-year-old\]~=5; Welch's correction \[p=0.8272,0.8926\], Mann-Whitney \[p=0.9444\]. On average, 15% of the insulin^+^ cells found were YFP-labeled, some of which no longer contained glucagon as in **(j)**, lower row. Note the decreased proportion of YFP-labeled insulin^+^ cells when α-cells are tagged late after ablation (from 80% to 15%; compare **(i)** and **(k)**), and the presence of YFP-labeled insulin^+^/glucagon-negative cells in the latter situation **(j)**, suggesting that bihormonal α-cells slowly but gradually lose glucagon gene activity. Scale bars are 20 μm. Error bars: standard deviation (s.d.).](nihms-610180-f0004){#F4}

![Diabetes recovery in pre-pubertal mice\
**a)** Evolution of glycemia ("AuC") between 2.5 and 4 mpa, in pups and adults (see [Fig 1b](#F1){ref-type="fig"}, Welch's test \[p=0.0188\]). **b)** qPCR of insulin2 mRNA after β-cell ablation; insulin2 transcripts are 25-fold more abundant in pups than in adults at 2 mpa (n=3 mice/group, each individual sample was run in triplicate in each reaction, for a total of 3 independent reactions); built-in Welch's test \[p=0.0134, 0.0049\], error bars: s.d.). **c)** Glucose tolerance tests (IPGTT) for DT-treated (4.5 mpa, n=4) and age-matched controls (n=4); note the fold-increase between glucose injection and the glycemic peak during IPGTT for each animal, and fold-decrease between glycemic peak and T120 (two-tailed unpaired t-test, \[p~(I)~=0.5836, p~(II)~=0.4937\]). **d)** Plasma insulin at T0, T15 and T30 during the IPGTT (*control:* n=4; *DT:* n=4; two-tailed paired t-test \[p=0.0008\]). **e)** Insulin tolerance tests (ITT) performed 1,5 year after β-cell ablation at 2 weeks of age (*controls:* n=7; *DT:* n=10). **f)** 4.5 months after β-cell ablation (at 2 weeks), 3 mice became normoglycemic and received a second treatment with DT. Ablation of regenerated insulin^+^-cells in recovered mice leads to the appearance of glucagon^+^/insulin^+^ cells, corresponding to the type of "α-cell-dependent" regeneration observed in adults (31% of insulin+ cells also contained glucagon, [Supp. Table S8](#SD1){ref-type="supplementary-material"}). Arrow: glucagon^+^/insulin^+^ bihormonal cell; error bars: s.e.m. **g)** β-cell proliferation is very low in regenerating pups ([Supp. Table S9](#SD1){ref-type="supplementary-material"}, *control:* n~\[1-mo-old\]~=3, 6,006 insulin^+^-cells scored, n~\[2-mo-old\]~=3, 6,358 insulin^+^-cells scored; *DT*: n~\[0.5mpa\]~=5, 412 insulin^+^-cells scored; n~\[1.5mpa\]~=3, 675 insulin^+^-cells scored; Welch's test \[p=0.1197, p=0.0688\], error bars: s.e.m.). **h)** Islet cell proliferation is increased (3.5-fold; Ki67^+^ cells) in islets of DT-treated pups at 0.5 mpa (*control:* n~(1-month-old)~=3, 95 islets scored; n~(1.5-month-old)~=3, 94 islets scored; n~(2-month-old)~=3, 90 islets scored; n~(2.5-month-old)~=3, 89 islets scored; n~(3-month-old\ ctrl)~=3, 91 islets scored; n~(3.5-month-old)~=3, 93islets scored; n~(18.5-month-old)~=3, 83 islets scored; 19~(19-month-old\ ctrl)~=3, 83 islets scored; n~(19.5-month-old)~=3, 88 islets scored; *DT(2-week-old)*: n~(0.5mpa)~=6, 333 islets scored; n~(1mpa)~=3, 91 islets scored; n~(1.5mpa)~=3, 90 islets scored; *DT(2-month-old)*: n~(0.5mpa)~=3, 76 islets scored; n~(1mpa)~=3, 77 islets scored; n~(1.5mpa)~=3, 81 islets scored; DT*(1.5-year-old):* n~(0.5mpa)~=3, 74 islets scored; n~(1mpa)~=3, 81 islets scored; n~(1.5mpa)~=3, 77 islets scored; error bars: s.d. Welch's test, one-way Anova \[p\<0.001\] Mann-Whitney \[p=0.0238\]). **i)** Ki67^+^ cells are hormone, chromogranin A-negative; lineage-traced α- and DT-spared β-cells are Ki67-negative. Scale bars: 20 μm.](nihms-610180-f0005){#F5}

![δ-cell labeling and tracing in transgenic mice\
**a)** The number of somatostatin^+^ cells transiently decreases by 80% during the 2^nd^ week after ablation (n~\[control\]~=255 islets, 7 mice; n~\[3dpa\]~=240 islets, 5 mice; n~\[5dpa\]~=228 islets, 5 mice; n~\[7dpa\]~=251 islets, 5 mice; n~\[0.5mpa\]~=267 islets, 6 mice; n~\[1mpa\]~=266 islets, 5 mice; n~\[1.5mpa\]~=206 islets, 5 mice; error bars: s.d.; Welch's test \[p=0.0008, 0.0229, 0.006, 0.035\], one-way Anova \[p\<0.0001\], Mann-Whitney \[p=0.0043\]). **b)** Relative somatostatin gene expression sharply decreases 2 weeks after β-cell ablation in 2-week-old mice (n=3 mice/group, each individual sample of each experimental group was run in triplicate, in 3 independent reactions); built-in Welch's test \[p=0.0002\], error bars: s.d.). **c)** *Somatostatin-Cre; R26-YFP* mice. Cre activity efficiently and specifically occurs in δ-cells (box: enlarged cell). Scale bar: 20 μm. **d)** Quantitative values of reporter gene expression in islet cells (n=4, 1,263 YFP^+^-cells scored).](nihms-610180-f0006){#F6}

![δ-cells dedifferentiate, proliferate and reprogram into insulin production after extreme β-cell loss in juvenile mice\
Observed and expected numbers of somatostatin^+^ and insulin^+^ cells per islet section, before and after β-cell ablation. Cells scored after 6 weeks ([Extended Data Fig. 3a](#F6){ref-type="fig"}) correspond (χ^2^ test) with estimates made assuming that dedifferentiated proliferating δ-cells yield 2 types of progeny (as deduced from [Fig. 2c,e](#F2){ref-type="fig"}). Dashed arrows, phenotypic stability; plain arrows, dynamic behavior (dedifferentiation and replication).](nihms-610180-f0007){#F7}

![Regeneration in streptozotocin-treated pups and DT-treated adults\
**a)** Immunofluorescence showing YFP-labeled insulin^+^ cells at 1.5 month following streptozotocin (STZ)-induced ablation of β-cells in 2-week-old mice. Arrows: YFP^+^/insulin^+^ cells; arrowhead: YFP^+^/somatostatin^+^ cell; asterisks: escaping β-cells. **b)** Number of remaining β-cells per islet section at 2 weeks after streptozotocin or DT treatment in pups, reflecting difference in ablation efficiency of the 2 methods ([Supp. Table S18](#SD1){ref-type="supplementary-material"})(n~\[STZ\]~=87 islets, 3 mice; n~\[DT\]~= 361 islets, 4 mice; Welch's test \[inter-islet p\<0.0001; inter-individual p=0.0109\], Mann-Whitney \[p\<0.001\]). **c)** The number of YFP^+^/insulin^+^ cells per islet section at 1.5 mpa is not significantly different between the two β-cell ablation methods ([Supp. Table S19](#SD1){ref-type="supplementary-material"})(n~\[STZ\]~=88 islets, 3 mice; n~\[DT\]~=193 islets, 7 mice; Welch's test \[p=0.4786\]). **d)** δ-cell numbers per islet section in controls (n=3, 174 islets scored), 0.5 mpa (n=4, 140 islets scored) and 1 mpa (n=3, 86 islets scored) (unpaired t-test, two-tailed, \[p=0.6386; p=0.5406\]). **e)** Immunofluorescence for YFP and Ki67 2 weeks (0.5 mpa) after DT, in *Somatostatin-Cre; R26-YFP; RIP-DTR* mice. **f)** Experimental design for δ-cell tracing in β-cell-ablated *Somatostatin-Cre; R26-YFP; RIP-DTR* mice at 2 months of age, and immunofluorescence for somatostatin, YFP and insulin at 1.5 mpa. Arrow: YFP^+^/insulin^+^/somatostatin^−^ cell. **g)** At 1.5 mpa, 17% of insulin^+^ cells coexpress YFP *vs*. almost 100% in ablated prepubescent mice (*control:* n=4; *DT:* n=8; unpaired t-test, two-tailed \[p=0.0462\]). **h)** At 1.5 mpa, 98% of the YFP^+^ cells are somatostatin^+^, and 1% are insulin^+^ cells (*vs*. 44% in mice ablated before puberty; n=8, unpaired t-test, two-tailed). Scale bars: 20 μm. Error bars: s.d.](nihms-610180-f0008){#F8}

![δ-to-β cell conversion after β-cell ablation is maintained in young islets ablated underneath the kidney capsule of adult hosts\
**a)** Islet transplantation design: 400-600 islets isolated from 2-week-old *Somatostatin-Cre; R26-YFP; RIP-DTR* transgenics were transferred under the kidney capsule of 2-month-old immunodeficient (SCID) mice (n=3). **b)** Experimental design: after one week of engraftment, adult host mice were DT-treated and left to regenerate for 6 weeks. **c)** δ- to-β conversion was observed in β-cell-ablated engrafted islets, like in the pancreas of juvenile mice. Scale bars: 20 μm](nihms-610180-f0009){#F9}

![Characterization of δ-cell-derived regenerated insulin^+^ cells\
Once differentiated from δ-cells (YFP^+^), the newly formed β-cells re-enter the cell cycle (Ki67^+^ cells). Two waves of massive replication occur, at 3 and 4 months after injury, respectively ([Supp. Table S23](#SD1){ref-type="supplementary-material"}). **b)** qPCR for β-cell-specific genes using RNA extracted from islets isolated from control and DT-treated mice, either 2 weeks or 4 months following DT administration ("0.5 mpa" and "4 mpa"). Note that after an initial extreme downregulation of all the β-cell-specific markers explored, their levels significantly recover after 4 months, which correlates with the observed robust regeneration and diabetes recovery. Values represent the ratio between each regeneration time-point and its age-matched control. **c)** Experimental design. **d)** qPCR comparison between regenerated cherry^+^/insulin^+^ cells isolated from mice 4 months after β-cell ablation, and cherry^+^ β-cells obtained from age-matched controls (4.5-month-old). All markers tested are expressed at identical levels in both groups; non-β-cell markers are expressed at extremely reduced levels (CT ranging from 28 to 31), showing the same degree of purity in both types of cell preparations. **e, f)** Interestingly, in contrast to *bona fide* β-cells isolated from 4.5-month-old controls, regenerated insulin^+^ cells have lower levels of cyclin-dependent kinase inhibitors, FoxO1 and Smad3. This correlates with their increased proliferative capacity at this specific time-point. Scale bars: 20 μm; qPCRs: n=3 mice/group, each individual sample of each experimental group was run in triplicate, in 3 independent reactions); built-in Welch's test; error bars: s.d.](nihms-610180-f0010){#F10}

![Ngn3 activation is required for insulin expression in dedifferentiated δ-cells\
**a)** qPCR for Ngn3 mRNA after β-cell ablation reveals a transitory 5-fold upregulation of Ngn3 transcripts 6 weeks after β-cell ablation when β-cell ablation is performed before puberty, but not in adult mice. (*controls:* n~\[1-month-old\]~=3, n~\[1.5-month-old\]~=3, n~\[2-month-old\]~=6, n~\[2.5-month-old\]~=3, n~\[2.5-month-old\]~=3, n~\[3-month-old\]~=3, n~\[3.5-month-old\]~=3, n~\[4-month-old\]~=3; *DT(2-week-old):* n~\[0.5mpa\]~=3, n~\[1mpa\]~=3, n~\[1.5mpa\]~=6, n~\[2mpa\]~=3; *DT(2-month-old):* n~\[0.5mpa\]~=3, n~\[1mpa\]~=3, n~\[1.5mpa\]~=3, n~\[2mpa\]~=3; each individual sample (mouse) was run in triplicate, in each one of 3 independent reactions; built-in Welch's test \[p=0.0112, 0.0178\]). **b)** Ngn3 transcriptional activity can be monitored in *Ngn3-YFP* knock-add-on mice because Ngn3 promoter activity results in YFP expression. In non-ablated age-matched control pups, or in ablated adults, no islet YFP^+^ cells were found (not shown), yet when β-cells are ablated at 2 weeks of age, 86% of insulin^+^ cells also express YFP^+^ at 1.5 mpa (*control:* n=3, 6,358 insulin^+^-cells scored *DT:* n=3, 675 insulin^+^-cells scored; Welch's test \[p=0.0010\]); **c)** At 1.5 mpa, 81% of YFP^+^ cells co-express insulin, but no glucagon, somatostatin or PP (not shown). Two weeks later, YFP^+^ cells are almost absent, reflecting the downregulation of Ngn3 expression reported in **a)**, and suggesting that insulin^+^ cells originate from cells transiently activating Ngn3 expression after ablation (*control:* n~\[1-month-old\]~=3; n~\[1.5-month-old\]~=3; n~\[2-month-old\]~=3; n~\[2.5-month-old\]~=3; absent YFP^+^-cells in all control conditions; *DT:* n~\[0.5mpa\]~=3, 31 YFP^+^-cells; n~\[1mpa\]~=3, 123 YFP^+^-cells; n~\[1.5mpa\]~=3, 729 YFP^+^-cells; n~\[2mpa\]~=3; 47 YFP^+^-cells; Welch's test and Anova \[p\<0.0001\]). **d)** Irreversible lineage-tracing of Ngn3-expressing cells at 1 and 1.5 mpa upon tamoxifen (TAM) administration in *Ngn3-CreERT; R26-YFP; RIP-DTR* mice; immunofluorescence analyses reveal that in absence of β-cell ablation, there is no YFP induction (controls). In ablated mice, nearly all insulin^+^ cells are YFP^+^ with time (arrows). At early time-points (1 mpa), YFP^+^/hormone-negative cells are found: these are likely differentiating cells before insulin expression. **e, f)** In β-cell-ablated *Ngn3-CreERT; R26-YFP; RIP-DTR* pups, 91% of insulin^+^ cells coexpress YFP^+^ (*control:* n=3, 3,472 insulin^+^-cells scored, *DT:* n=3, 489 insulin^+^-cells scored) (**e**) and inversely, 93% of the YFP^+^ cells are insulin^+^ (**f**) (*control:* n=3; absent YFP^+^-cells in all control conditions, *DT:* n=3, 478 YFP^+^-cells scored). **g)** Experimental design to block Ngn3 upregulation in β-cell-ablated prepubescent mice, by administrating DOX to mice bearing 5 mutant alleles: *Ngn3-tTA^+/+^; TRE-Ngn3^+/+^; RIP-DTR*. In these mice the Ngn3 coding region is replaced by a DOX-sensitive transactivator gene (tTA); the endocrine pancreas develops normally because Ngn3 expression is allowed in absence of DOX by the binding of tTA to the promoter of *TRE-Ngn3* transgene. Pups were given DT at 2 weeks of age and then DOX 2 weeks later, to block Ngn3 upregulation. They were euthanized when Ngn3 peaks after ablation (2-month-old).**h)** Islets from non-ablated ("no DT") and ablated ("DT") mice, exposed (Ngn3 inhibition) or not (normal Ngn3 expression) to DOX treatment from 4 weeks of age. β-cell regeneration is efficient in absence of DOX (as previously shown), but decreases after Ngn3 blockade, resulting in the appearance of glucagon/insulin bihormonal cells. **i)** Sharply decreased regeneration by blocking Ngn3 expression in DOX-treated mice reveals the requirement of Ngn3 for efficient β-cell regeneration in pups (*DT:* n=266 islets scored, 3 mice; *DT+DOX*: n=167, 4 mice; Welch's test \[inter-islet p\<0.0001; inter-animal p=0.0352\], Mann-Whitney \[p\<0.0001\]). **j)** glucagon+/insulin+ bihormonal cells appear in DOX-treated β-cell-ablated pups (Ngn3 inhibition), suggesting a switch to an "adult-like", less efficient, mechanism of regeneration (*control+DOX:* n=3, 9233 insulin^+^-cells scored; *DT:* n=3 1385 insulin^+^-cells scored; *DT+DOX*: n=4, 141 insulin^+^-cells scored; Welch's test \[p=0.0081\], Anova \[p\<0.0001\]). **k)** Combined double lineage tracing of δ-cells (Tomato^+^) and Ngn3-expressing cells (YFP^+^) show by immunofluorescence that nearly all insulin^+^ cells express both reporters, but no somatostatin (arrows). Somatostatin^+^ cells (arrowheads) are YFP- and insulin-negative. Scale bars: 20 μm. Error bars: s.d.](nihms-610180-f0011){#F11}

![FoxO1 regulatory network\
**a)** Cartoon depicting the FoxO1 network involved in the regulation of cell cycle progression and cellular senescence: FoxO1 arrests the cell cycle by repressing activators (cyclinD1, cyclinD2) and inducing inhibitors (cdkn1a/p21, cdkn1b/p27, cdkn2b/p15Ink4b, cdkn1c/p57) \[PMID: 10102273; PMID: 17873901\]. cdkn1a/p21 and cdkn2b/p15Ink4b activation, a sign of cellular senescence \[PMID: 17667954\], is regulated by FoxO1 through direct interaction with Skp2 protein. In turn, Skp2 blocks FoxO1 and, together with CKS1b, CDK1 and CDK2, triggers the direct degradation of cdkn1a/p21 and cdkn1b/p27, thus promoting proliferation \[PMID: 15668399\]. FoxO proteins are inhibited mainly through PI3K/AKT-mediated phosphorylation \[PMID: 10102273, PMID: 12621150, PMID: 21708191, PMID: 10217147, PMID: 17604717\]: PDK1, the master kinase of the pathway, stimulates cell proliferation and survival by directly activating AKT, which phosphorylates (inhibits) the FoxOs \[PMID: 10698680, PMID: 19635472\]. PI3K/AKT/FoxO1 circuit requires active TGFβ/SMAD signaling \[PMID: 24238962, PMID: 15084259\] in order to co-regulate cdkn1a/p21-dependent cell senescence. Active TGFβ signaling downregulates the BMP pathway downstream effectors ID1 and ID2, known to promote dedifferentiation and proliferation during embryogenesis and cancer progression, probably through cdkn2b/p15Ink4b regulation \[PMID: 11840321, PMID: 16034366\]. **b)** β-cell ablation in adults triggers FoxO1 upregulation and the subsequent cell cycle arrest in δ-cells.](nihms-610180-f0012){#F12}

![δ-cell dedifferentiation in adult mice upon transient FoxO1 inhibition\
**a-d)** The 1 week FoxO1 inhibition with the compound AS1842856 in control unablated adult mice (**a**) results in dedifferentiation of one-fourth of the δ-cell population (**b;** [Supp. Table S30](#SD1){ref-type="supplementary-material"}, *treated*: n=3, 1,347 YFP^+^-cells scored; *untreated*: n=4, 1,224, YFP^+^-cells scored; error bars: s.d.), without leading to insulin (**c;** [Supp. Table S31](#SD1){ref-type="supplementary-material"}, *treated*: n=3, 3,249 insulin^+^-cells scored; *untreated*: n=4, 9,562 insulin^+^-cells scored; error bars: s.d.; Welch's test \[p=0.1590\]) or glucagon (**d;** [Supp. Table S32](#SD1){ref-type="supplementary-material"}, *treated:* n=2, 728 YFP^+^-cells scored; error bars: s.e.m.) expression. **e)** One month following FoxO1 transient inhibition in β-cell-ablated adults, dedifferentiated δ-cells do not express glucagon ([Supp. Table S36](#SD1){ref-type="supplementary-material"}, *treated:* n=2, 986 YFP^+^-cells scored; error bars: s.e.m.). **f)** Transient FoxO1 inhibition long-time (1 month) after β-cell ablation also leads to the appearance of lineage-traced dedifferentiated δ-cells that express insulin ([Supp. Table S37](#SD1){ref-type="supplementary-material"}-[39](#SD1){ref-type="supplementary-material"}, *treated:* n=3, 71 islets scored; 300 insulin^+^-cells scored; 1216 YFP^+^-cells scored; error bars: s.d.). Scale bars: 20 μm.](nihms-610180-f0013){#F13}
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![β-cell ablation before puberty and diabetes recovery\
**a)** Experimental designs depicting the ages at DT-administration and the various analyses ("mpa", months post-ablation). **b)** Comparative evolution of glycemia in β-cell-ablated younglings (n=5) and middle-aged adults (n=4); 2.5 months after β-cell ablation, insulin administration was stopped (Mann-Whitney \[p=0.0014\]). **c)** Islets from 2-week-old ("control"), 0.5 mpa and 4 mpa ([Supp. Table S6](#SD1){ref-type="supplementary-material"}). **d)** α-cell tracing in pups. Scale bars: 20μm.](nihms-610180-f0001){#F1}

![δ-cells dedifferentiate, proliferate and reprogram into insulin production after extreme β-cell loss in *Somatostatin-Cre; R26-YFP; RIP-DTR* juvenile mice\
**a)** Immunofluorescence for YFP and Ki67 at 0.5 mpa. **b)** 80% of somatostatin-traced YFP^+^ cells are Ki67^+^ after β-cell-ablation (*controls:* n=6, 2,754 YFP^+^-cells scored; *DT:* n=6; 3,146 YFP^+^-cells scored; Welch's test \[p\<0.0001\], Mann-Whitney \[p=0.0022\]). **c, d)** At 1.5 mpa 90% of insulin+ cells coexpress YFP (*controls:* n=3, 6,480 insulin^+^-cells scored;*DT:* n=7, 1,592 insulin^+^-cells scored; Welch's test \[p\<0.0001\], Mann-Whitney \[p=0.0167\]). Arrow: YFP^+^/somatostatin^+^ cells; arrowhead: YFP^+^/insulin^+^ cells;. **e)** In controls, 99.9% of the YFP^+^ cells are somatostatin^+^ (n=3, 1,673 YFP^+^-cells scored). In contrast, at 1.5 mpa only 55% of the YFP^+^ cells are somatostatin^+^, while 45% of the YFP^+^ cells are insulin^+^ (n=5, 2,295 YFP^+^-cells scored; Welch's test \[p\<0.0001\], Mann-Whitney \[p=0.0357\]). **f)** Comparative evolution of glycemia after β-cell (n=5), δ-cell (n=4) and β- & δ-cell co-ablation (n=5) in younglings. **g**) δ-cell conversion sequence. Scale bars: 20 μm. Error bars: s.d.](nihms-610180-f0002){#F2}

![Age-dependent effect of β-cell loss on δ-cells\
**a, b)** Transcriptional variation of cell cycle regulators, PI3K/AKT/FoxO1 network genes **(a),** and TGFβ and BMP components and effectors **(b)** in juvenile and adult δ cells 1 week after ablation, as compared with age-matched controls. **c)** β-cell loss before puberty triggers FoxO1 downregulation in δ-cells, while the opposite occurs in adults (see [Extended Data **Fig.9b**](#F12){ref-type="fig"}). **d)** Experimental design to transiently inhibit FoxO1 in β-cell-ablated adult mice. **e)** Induction of δ-to-insulin cell conversion in diabetic adult mice. Scale bars: 20 μm. **f,g)** Insulin^+^ cells are 11-fold more abundant in FoxO1 inhibitor-treated mice (*treated*: n=190 islets, 4 mice; *untreated:* n=95 islets, 3 mice (Welch's test \[inter-islet p\<0.0001, inter-individual p=0.0065\], Mann-Whitney \[p\<0.0001\]) (**f**), and they are YFP^+^ (93%) (*treated:* n=4, 894 insulin^+^-cells scored; *untreated:* n=6, 370 insulin^+^-cells scored, Welch's test \[p\<0.0001\], Mann-Whitney \[p=0.0095\]) (**g**). **h)** One fourth of δ-(YFP^+^) cells in adult β-cell-ablated FoxO1-inhibited mice dedifferentiate and become insulin expressers (*treated*: n=4, 3,358 YFP^+^-cells scored; *untreated*: n=6, 2,559 YFP^+^-cells scored). Error bars: s.d.](nihms-610180-f0003){#F3}
